Theodore Logan

  • 6084 Citations
  • 35 h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1983 2019

  • 6084 Citations
  • 35 h-Index
  • 68 Article
  • 1 Letter
2019
1 Citation (Scopus)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Voss, M. H., Bhatt, R. S., Vogelzang, N. J., Fishman, M., Alter, R. S., Rini, B. I., Beck, J. T., Joshi, M., Hauke, R., Atkins, M. B., Burgess, E., Logan, T., Shaffer, D., Parikh, R., Moazzam, N., Zhang, X., Glasser, C., Sherman, M. L. & Plimack, E. R., Jan 1 2019, In : Cancer.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Placebos
Disease-Free Survival
axitinib
Human ALK1-Fc fusion protein
2018
5 Citations (Scopus)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Clark, J. I., Singh, J., Ernstoff, M. S., Lao, C. D., Flaherty, L. E., Logan, T., Curti, B., Agarwala, S. S., Taback, B., Cranmer, L., Lutzky, J., Luna, T. L., Aung, S. & Lawson, D. H., Jul 27 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 76.

Research output: Contribution to journalArticle

Interleukin-2
Melanoma
Mutation
Antigen Presentation
Neoplasm Antigens
1 Citation (Scopus)

NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma

Tarhini, A. A., Frankel, P., Ruel, C., Ernstoff, M. S., Kuzel, T. M., Logan, T., Khushalani, N. I., Tawbi, H. A., Margolin, K. A., Awasthi, S., Butterfield, L. H., McDermott, D., Chen, A., Lara, P. N. & Kirkwood, J. M., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Interleukin-2
Melanoma
Vascular Endothelial Growth Factor A
Confidence Intervals
Disease-Free Survival
117 Citations (Scopus)

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma

Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., Logan, T., Hauschild, A., Lebbé, C., Chen, L., Kim, J. J., Gansert, J., Andtbacka, R. H. I. & Kaufman, H. L., Jun 10 2018, In : Journal of Clinical Oncology. 36, 17, p. 1658-1667 10 p.

Research output: Contribution to journalArticle

Melanoma
Safety
ipilimumab
Oncolytic Viruses
Chills
2017
5 Citations (Scopus)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: Data from the PROCLAIMSM registry

Curti, B., Daniels, G. A., McDermott, D. F., Clark, J. I., Kaufman, H. L., Logan, T., Singh, J., Kaur, M., Luna, T. L., Gregory, N., Morse, M. A., Wong, M. K. K. & Dutcher, J. P., Dec 19 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 102.

Research output: Contribution to journalArticle

Interleukin-2
Registries
Survival
Neoplasms
Therapeutics
68 Citations (Scopus)

Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

Segal, N. H., Logan, T., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M. & Levy, R., Apr 15 2017, In : Clinical Cancer Research. 23, 8, p. 1929-1936 8 p.

Research output: Contribution to journalArticle

Monoclonal Antibodies
Safety
Liver Function Tests
Therapeutics
Nausea
2016
28 Citations (Scopus)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Alva, A., Daniels, G. A., Wong, M. K. K., Kaufman, H. L., Morse, M. A., McDermott, D. F., Clark, J. I., Agarwala, S. S., Miletello, G., Logan, T., Hauke, R. J., Curti, B., Kirkwood, J. M., Gonzalez, R., Amin, A., Fishman, M., Agarwal, N., Lowder, J. N., Hua, H., Aung, S. & 1 others, Dutcher, J. P., Oct 6 2016, (Accepted/In press) In : Cancer Immunology and Immunotherapy. p. 1-12 12 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interleukin-2
Melanoma
Survival
Therapeutics
133 Citations (Scopus)

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial

Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., Lusk, C. M., Oberg, S. & George, D. J., Mar 1 2016, In : The Lancet Oncology. 17, 3, p. 378-388 11 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Renal Cell Carcinoma
Therapeutics
Hand-Foot Syndrome
Clear-cell metastatic renal cell carcinoma
155 Citations (Scopus)

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T., Schuchter, L. M., Nair, S., Fecher, L., Buchbinder, E. I., Berghorn, E., Ruisi, M., Kong, G., Jiang, J., Horak, C. & Hodi, F. S., Jul 1 2016, In : The Lancet Oncology. 17, 7, p. 943-955 13 p.

Research output: Contribution to journalArticle

Melanoma
Survival
ipilimumab
nivolumab
Therapeutics
2015
18 Citations (Scopus)

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: Clinical implications for targeted therapy

Bradish, J. R., Richey, J. D., Post, K. M., Meehan, K., Sen, J. D., Malek, A. J., Katona, T. M., Warren, S., Logan, T., Fecher, L. A. & Cheng, L., Apr 8 2015, In : Modern Pathology. 28, 4, p. 480-486 7 p.

Research output: Contribution to journalArticle

Melanoma
Mutation
Therapeutics
Molecular Targeted Therapy
Neoplasms
540 Citations (Scopus)

Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T., Margolin, K. A., Plimack, E. R., Lambert, A. M., Waxman, I. M. & Hammers, H. J., May 1 2015, In : Journal of Clinical Oncology. 33, 13, p. 1430-1437 8 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Safety
Vascular Endothelial Growth Factor A
Fatigue
86 Citations (Scopus)

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Amin, A., Dudek, A. Z., Logan, T., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., Tcherepanova, I. Y., DeBenedette, M. A., Williams, W. L., Plessinger, D. C., Nicolette, C. A. & Figlin, R. A., Apr 21 2015, In : Journal for ImmunoTherapy of Cancer. 3, 1, 14.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Immunotherapy
Dendritic Cells
Survival
Disease-Free Survival
72 Citations (Scopus)

The high-dose aldesleukin "select" trial: A trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

McDermott, D. F., Cheng, S. C., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T., Curti, B. D., Ernstoff, M. S., Appleman, L., Wong, M. K. K., Khushalani, N. I., Oleksowicz, L., Vaishampayan, U. N., Mier, J. W., Panka, D. J., Bhatt, R. S., Bailey, A. S., Leibovich, B. C. & 7 others, Kwon, E. D., Kabbinavar, F. F., Belldegrun, A. S., Figlin, R. A., Pantuck, A. J., Regan, M. M. & Atkins, M. B., Feb 1 2015, In : Clinical Cancer Research. 21, 3, p. 561-568 8 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interleukin-2
Neoplasms
Ligands
Survival
4 Citations (Scopus)
Renal Cell Carcinoma
Perfusion
Water
Perfusion Imaging
Neoplasms
2014
161 Citations (Scopus)

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: A phase 1b study

Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., Flaherty, L., Logan, T., Chmielowski, B., Lewis, K., Kee, D., Boasberg, P., Yin, M., Chan, I., Musib, L., Choong, N., Puzanov, I. & McArthur, G. A., 2014, In : The Lancet Oncology. 15, 9, p. 954-965 12 p.

Research output: Contribution to journalArticle

Melanoma
Maximum Tolerated Dose
Poisons
PLX4032
GDC-0973
9 Citations (Scopus)

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma

Lam, E. T., Wong, M. K. K., Agarwal, N., Redman, B. G., Logan, T., Gao, D., Flaig, T. W., Lewis, K., Poust, J., Monk, P., Jarkowski, A., Sendilnathan, A., Bolden, M., Kuzel, T. M. & Olencki, T., 2014, In : Journal of Immunotherapy. 37, 7, p. 360-365 6 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Interleukin-2
Safety
Exercise Test
2013
13 Citations (Scopus)

Foretinib (XL880): C-MET inhibitor with activity in papillary renal cell cancer

Logan, T., Apr 2013, In : Current Oncology Reports. 15, 2, p. 83-90 8 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
GSK 1363089
Clinical Trials
Vascular Endothelial Growth Factor Receptor-2
Kidney Neoplasms
260 Citations (Scopus)

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., Ottesen, L. H., Laubscher, K. H., Sherman, L., McDermott, D. F., Haas, N. B., Flaherty, K. T., Ross, R., Eisenberg, P., Meltzer, P. S., Merino, M. J. & 3 others, Bottaro, D. P., Linehan, W. M. & Srinivasan, R., Jan 10 2013, In : Journal of Clinical Oncology. 31, 2, p. 181-186 6 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Biomarkers
Germ-Line Mutation
TIE-2 Receptor
GSK 1363089
2012
76 Citations (Scopus)

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Grünwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J. P., Lee, S. H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., Bodrogi, I., Romedi, M., Ferrandini, S. & 249 others, Rondinon, M., Pittman, K., Goldstein, D., Shapiro, J., Troon, S., Yip, D., Mainwaring, P., Zigeuner, R., Loidl, W., Greil, R. F., Schmidinger, M., De Grève, J., Rottey, S., Vermorken, J., Machiels, J., Gil, T., Gennigens, C., Roumeguere, T., Barrios, C., Mathias, C., Assi, H., Hotte, S., Karakiewicz, P., Knox, J., Spadafora, S., Wood, L., Zalewski, P., Mackensie, M., Bjarnason, G., Lalancette, A., Chan, A., Higgins, B., North, S., Soulieres, D., Asselah, J., Sperlich, C., Miller, W., Yadav, S., El-Maraghi, R., Godoy, J., Prausová, J., Katolicka, J., Petruzelka, L., Kiss, I., Bono, P., Lapela, M., Miller, K., Bergmann, L., Beck, J., Jäger, E., Kindler, M., Overkamp, F., Wirth, M., Hölzer, W., Gschwend, J., Stenzl, A., Gauler, T., Niederwieser, D., Marschner, N., Lück, A., Tessen, H., Eichelberg, C., Steiner, T., Goebell, P., Kettner, E., Bakhshandeh-Bath, A., Wilhelm, M., Schmitz, S., Jacob, A., Bierer, S., Kube, U., Staehler, M., Engel, E., Frambach, M., Schellenberger, U., Albers, P., Simon, J., Gleissler, M., Klotz, T., Repp, R., Kröning, H., Westermann, J., Rebmann, U., Brehmer, B., Niederle, N., Grund, C., Verpoort, K., Fonara, P., Rassweiler, J., Bamias, A., Fountzilas, G., Razis, E., Mouratidou, D., Georgoulias, V., Samantas, E., Bodrogi, I., Mangel, L., Szanto, J., Berger, R., Pe'er, A., Sella, A., Ben-Yosef, R., Nechushtan, H., Crinò, L., Bracarda, S., Ciuffreda, L., Graiff, C., Falcone, A., Roselli, M., Sternberg, C., Santoro, A., Ruggeri, E., Bearz, A., Venturini, M., Aglietta, M., Amadori, D., Di Costanzo, F., Bari, M., Gebbia, N., Conte, P., Bonetti, A., Bordonaro, R., Cascinu, S., Contu, A., Cruciani, G., Gasparro, D., Nardi, M., Lelli, G., Lo Re, G., Boccardo, F., Lorusso, V., Maiello, E., Manente, P., Passalacqua, R., Piantedosi, F., Porta, C., Sacco, C., Tondini, C., De Placido, S., Carteni, G., Dogliotto, L., Rosti, G., Milella, M., Roila, F., Amoroso, D., Farina, G., Al-Khatib, H., Lee, S., Kim, T., Ahn, J., Lim, H., Rha, S., Chung, I., Kim, J., Chung, J., Ghosn, M., Shameseddine, A., Lugo, R., Cabrera, P., Osanto, S., Groenewegen, G., Blank, C., van den Eertwegh, F., van Herpen, C., Oosting, S., Soetekouw, P., Lilleby, W., Klepp, O., Guren, T., Alcedo, J., Karlov, P., Nosov, D., Roman, L., Rusakov, I., Bazarbashi, S., Toh, C., Mardiak, J., Constenla, M., Solans, F. G. D. M., Maroto Ray, J., Bellmunt Mollins, J., Castellano, D., Duran Martinez, I., Mellado Gonzalez, B., Domenech Santasusana, M., Lopez-Brea Piqueras, M., Campillo Fuentes, J., Gonzalez Larriba, J., Luque Caro, R., Meana Garcia, A., Aparicio, L., Batista Lopez, N., Calderero Aragon, V., Valverde Morales, C., Figueiras, M., Contreras Ibanez, J., Gonzalez Billalabeitia, E., Estrada, E., Arranz, J., Lambea Sorrosal, J., Lozano, A., de Villena, M. C., Espinosa, E., Lopez, R., Perez Garcia, J., Laurell, A., Stierner, U., Cwikiel, M., Borner, M., Dietrich, P. Y., Rothermundt, C., Pu, Y., Chang, Y., Ou, Y., Chuang, C., Liao, Y., Srimuninnimit, V., Sriuranpong, V., Buyukberber, S., Yalcin, B., Goker, E., Yalcin, S., Geldart, T., Wagstaff, J., Nicholson, S., Chowdhury, S., Bahl, A., Jones, R., Azzabi, A., Chao, D., Fife, K., Hawkins, R., Mead, G., Nathan, P., Pandha, H., Hajdenberg, J., Gabrail, N., Nimeh, N., Logan, T., Flaig, T., Schraeder, R., Rini, B., O'Rourke, M., Alemany, C., Beck, J., Kessinger, A., Amin, A., Arriaga, M. & Rodriguez, J., Feb 2012, In : European Journal of Cancer. 48, 3, p. 324-332 9 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Renal Cell Carcinoma
Protein-Tyrosine Kinases
Safety
Compassionate Use Trials
47 Citations (Scopus)

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Nanoparticles
Disease Progression
2-methoxyestradiol
sunitinib
572 Citations (Scopus)

Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T., Richards, J., Michener, T., Balogh, A., Heller, K. N. & Hodi, F. S., May 2012, In : The Lancet Oncology. 13, 5, p. 459-465 7 p.

Research output: Contribution to journalArticle

Melanoma
Neoplasm Metastasis
Brain
Hyperglycemia
ipilimumab
29 Citations (Scopus)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

Ribas, A., Chesney, J. A., Gordon, M. S., Abernethy, A. P., Logan, T., Lawson, D. H., Chmielowksi, B., Glaspy, J. A., Lewis, K., Huang, B., Wang, E., Hsyu, P. H., Gomez-Navarro, J., Gerhardt, D., Marshall, M. A. & Gonzalez, R., Nov 21 2012, In : Journal of Translational Medicine. 10, 1, 236.

Research output: Contribution to journalArticle

Pharmacokinetics
Anti-Idiotypic Antibodies
Safety
Antibodies
Melanoma
2011
85 Citations (Scopus)

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus

Maroto, J. P., Hudes, G., Dutcher, J. P., Logan, T., White, C. S., Krygowski, M., Cincotta, M., Shapiro, M., Duran, I. & Berkenblit, A., May 1 2011, In : Journal of Clinical Oncology. 29, 13, p. 1750-1756 7 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Pneumonia
Pharmaceutical Preparations
Interferons
Arm
2010
109 Citations (Scopus)

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., Hammershaimb, L. & Kirkwood, J. M., Mar 15 2010, In : Cancer. 116, 6, p. 1526-1534 9 p.

Research output: Contribution to journalArticle

Integrin beta3
Dacarbazine
Melanoma
Monoclonal Antibodies
etaracizumab
2009
42 Citations (Scopus)

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma

Tarhini, A. A., Millward, M., Mainwaring, P., Kefford, R., Logan, T., Pavlick, A., Kathman, S. J., Laubscher, K. H., Dar, M. M. & Kirkwood, J. M., Feb 15 2009, In : Cancer. 115, 4, p. 859-868 10 p.

Research output: Contribution to journalArticle

Melanoma
Lymphopenia
Fatigue
Proxy
Pleural Effusion

Prognostic Implications of Polymorphisms and Interleukin-2 Therapy for Renal Cell Carcinoma

Gardner, T. & Logan, T., Aug 2009, In : Journal of Urology. 182, 2, p. 425-426 2 p.

Research output: Contribution to journalArticle

Kidney Neoplasms
Renal Cell Carcinoma
Antineoplastic Agents
Interleukin-2
Therapeutics
2008
57 Citations (Scopus)

A dose-escalation study of recombinant human Lnterleukin-18 using two different schedules of administration in patients with cancer

Robertson, M., Kirkwood, J. M., Logan, T., Koch, K. M., Kathman, S., Kirby, L. C., Bell, W. N., Weisenbach, J., Thurmond, L. M. & Dar, M. M., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3462-3469 8 p.

Research output: Contribution to journalArticle

Appointments and Schedules
Lymphopenia
Interleukin-18
Pharmacokinetics
Hypoalbuminemia
69 Citations (Scopus)

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II cytokine working group study

Atkins, M. B., Sosman, J. A., Agarwala, S., Logan, T., Clark, J. I., Ernstoff, M. S., Lawson, D., Dutcher, J. P., Weiss, G., Curti, B. & Margolin, K. A., Oct 15 2008, In : Cancer. 113, 8, p. 2139-2145 7 p.

Research output: Contribution to journalArticle

temozolomide
Thalidomide
Melanoma
Radiotherapy
Cytokines
2007
6 Citations (Scopus)

Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: A cytokine working group study

Clark, J. I., Mehrabi, J., Sosman, J. A., Logan, T., Margolin, K. A., Dutcher, J. P., Urba, W. J., Ernstoff, M. S., McDermott, D. F., Lau, A. M. & Atkins, M. B., Nov 2007, In : Journal of Immunotherapy. 30, 8, p. 839-846 8 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interferons
Interleukin-2
Outpatients
Cytokines
Renal Cell Carcinoma
sunitinib

Urticaria and angioedema in renal cell cancer patients treated with IL-2

Logan, T., Strippoli, G. & Levine, M. I., Oct 2007, In : Cancer Investigation. 25, 7, p. 584-588 5 p.

Research output: Contribution to journalArticle

Angioedema
Urticaria
Renal Cell Carcinoma
Interleukin-2
Anaphylaxis
2006
35 Citations (Scopus)

Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study

Rini, B. I., Halabi, S., Barrier, R., Margolin, K. A., Avigan, D., Logan, T., Stadler, W. M., McCarthy, P. L., Linker, C. A. & Small, E. J., Jul 2006, In : Biology of Blood and Marrow Transplantation. 12, 7, p. 778-785 8 p.

Research output: Contribution to journalArticle

Adoptive Immunotherapy
Stem Cell Transplantation
Renal Cell Carcinoma
Graft vs Host Disease
Liver Failure
91 Citations (Scopus)

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.

Robertson, M., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., Pandite, L. N., Oei, C., Kirby, L. C., Jewell, R. C., Bell, W. N., Thurmond, L. M., Weisenbach, J., Roberts, S. & Dar, M. M., Jul 15 2006, In : Clinical Cancer Research. 12, 14 Pt 1, p. 4265-4273 9 p.

Research output: Contribution to journalArticle

Interleukin-18
Intravenous Infusions
Neoplasms
Hypotension
Pharmacokinetics
7 Citations (Scopus)

Interleukins 18 and 21: Biology, mechanisms of action, toxicity, and clinical activity

Logan, T. F. & Robertson, M. J., Mar 2006, In : Current Oncology Reports. 8, 2, p. 114-119 6 p.

Research output: Contribution to journalArticle

Interleukin-18
Neoplasms
Clinical Trials, Phase I
Interleukins
Animal Models
2005
127 Citations (Scopus)

Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma

Wagner, J. D., Schauwecker, D., Davidson, D., Logan, T., Coleman, J. J., Hutchins, G., Love, C., Wenck, S. & Daggy, J., Aug 1 2005, In : Cancer. 104, 3, p. 570-579 10 p.

Research output: Contribution to journalArticle

Positron-Emission Tomography
Melanoma
Glucose
Skin
Neoplasm Metastasis
165 Citations (Scopus)

Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies

Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., Ensor, C. M., Prestayko, A. W., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., Savaraj, N., Feun, L. G. & Logan, T., 2005, In : Journal of Clinical Oncology. 23, 30, p. 7660-7668 9 p.

Research output: Contribution to journalArticle

Melanoma
Arginine
Therapeutics
Pharmacokinetics
Essential Amino Acids
613 Citations (Scopus)

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., Tretter, C. P. G., Urba, W. J., Smith, J. W., Margolin, K. A., Mier, J. W., Gollob, J. A., Dutcher, J. P. & Atkins, M. B., Jan 1 2005, In : Journal of Clinical Oncology. 23, 1, p. 133-141 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interferons
Interleukin-2
interferon alfa-2b
Neoplasm Metastasis
94 Citations (Scopus)

Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma

Burczynski, M. E., Twine, N. C., Dukart, G., Marshall, B., Hidalgo, M., Stadler, W. M., Logan, T., Dutcher, J., Hudes, G., Trepicchio, W. L., Strahs, A., Immermann, F., Slonim, D. K. & Dorner, A. J., Feb 1 2005, In : Clinical Cancer Research. 11, 3, p. 1181-1189 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Blood Cells
Survival
Kidney Neoplasms
Gene Expression Profiling
2004
859 Citations (Scopus)

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S. H., Marshall, B., Boni, J. P., Dukart, G. & Sherman, M. L., 2004, In : Journal of Clinical Oncology. 22, 5, p. 909-918 10 p.

Research output: Contribution to journalArticle

Sirolimus
Renal Cell Carcinoma
Phosphotransferases
Survival
Pharmacokinetics
2003
237 Citations (Scopus)

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial

Clark, J. I., Atkins, M. B., Urba, W. J., Creech, S., Figlin, R. A., Dutcher, J. P., Flaherty, L., Sosman, J. A., Logan, T., White, R., Weiss, G. R., Redman, B. G., Tretter, C. P. G., McDermott, D., Smith, J. W., Gordon, M. S. & Margolin, K. A., Aug 15 2003, In : Journal of Clinical Oncology. 21, 16, p. 3133-3140 8 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interleukin-2
Cytokines
Observation
Metastasectomy
109 Citations (Scopus)

Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma

Twine, N. C., Stover, J. A., Marshall, B., Dukart, G., Hidalgo, M., Stadler, W., Logan, T., Dutcher, J., Hudes, G., Dorner, A. J., Slonim, D. K., Trepicchio, W. L. & Burczynski, M. E., Sep 15 2003, In : Cancer Research. 63, 18, p. 6069-6075 7 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Blood Cells
Transcriptome
Neoplasms
Healthy Volunteers
54 Citations (Scopus)

MAGE-6 encodes HLA-DRβ1*0401-presented Epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma

Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Brusic, V., Sidney, J., Sette, A., Logan, T., Kasamon, Y. L., Slingluff, C. L., Kirkwood, J. M. & Storkus, W. J., Mar 1 2003, In : Clinical Cancer Research. 9, 3, p. 947-954 8 p.

Research output: Contribution to journalArticle

HLA-DR1 Antigen
Renal Cell Carcinoma
Epitopes
Melanoma
HLA-DR4 Antigen
18 Citations (Scopus)

Nephrectomy for metastatic renal cell carcinoma: Indiana University experience

Mosharafa, A., Koch, M., Shalhav, A., Gardner, T., Logan, T., Bihrle, R. & Foster, R., Oct 1 2003, In : Urology. 62, 4, p. 636-640 5 p.

Research output: Contribution to journalArticle

Nephrectomy
Renal Cell Carcinoma
Immunotherapy
Morbidity
Intraoperative Complications
64 Citations (Scopus)

Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma

Wagner, J. D., Ranieri, J., Evdokimow, D. Z., Logan, T., Chuang, T. Y., Johnson, C. S., Jung, S. H., Wenck, S. & Coleman, J. J., Aug 2003, In : Plastic and Reconstructive Surgery. 112, 2, p. 486-497 12 p.

Research output: Contribution to journalArticle

Sentinel Lymph Node Biopsy
Lymph Node Excision
Melanoma
Recurrence
Lymph Nodes
2002
20 Citations (Scopus)

Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial

Logan, T., Jadali, F., Egorin, M. J., Mintun, M., Sashin, D., Gooding, W. E., Choi, Y., Bishop, H., Trump, D. L., Gardner, D., Kirkwood, J., Vlock, D. & Johnson, C., 2002, In : Cancer Chemotherapy and Pharmacology. 50, 6, p. 433-444 12 p.

Research output: Contribution to journalArticle

Positron emission tomography
Carboplatin
Interleukin-1
Positron-Emission Tomography
Tumors
2 Citations (Scopus)
Cell Transplantation
Renal Cell Carcinoma
Transplants
Graft vs Host Disease
Hematologic Neoplasms
106 Citations (Scopus)

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

Zarour, H. M., Maillere, B., Brusic, V., Coval, K., Williams, E., Pouvelle-Moratille, S., Castelli, F., Land, S., Bennouna, J., Logan, T. & Logan, T., Jan 1 2002, In : Cancer Research. 62, 1, p. 213-218 6 p.

Research output: Contribution to journalArticle

Major Histocompatibility Complex
Epitopes
T-Lymphocytes
Peptides
Melanoma
2001
52 Citations (Scopus)

Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases

Fakih, M., Schiff, D., Erlich, R. & Logan, T., 2001, In : Annals of Oncology. 12, 8, p. 1173-1177 5 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Spinal Cord
Neoplasm Metastasis
Terminally Ill
Case Management
2000
15 Citations (Scopus)

A painful cutaneous nodule as the presentation of metastatic transitional cell carcinoma of the renal pelvis

Zirwas, M. J., Hunt, S., Logan, T., Abernethy, J. L. & Seraly, M. P., May 2000, In : Journal of the American Academy of Dermatology. 42, 5 II, p. 867-868 2 p.

Research output: Contribution to journalArticle

Kidney Pelvis
Transitional Cell Carcinoma
Skin
Neoplasm Metastasis
Blood Vessels
82 Citations (Scopus)

Phase II trial of interleukin 2, interferon α and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group Study

Dutcher, J. P., Logan, T., Gordon, M., Sosman, J., Weiss, G., Margolin, K., Plasse, T., Mier, J., Lotze, M., Clark, J. & Atkins, M., 2000, In : Clinical Cancer Research. 6, 9, p. 3442-3450 9 p.

Research output: Contribution to journalArticle

Interleukin-5
Renal Cell Carcinoma
Fluorouracil
Interferons
Interleukin-2